文献速递心血管MRUS

心肌淀粉样变性:间质疾病的典型代表

Myocardial Amyloidosis: The Exemplar Interstitial Disease.
PubMed 文献 · JACC Cardiovasc Imaging · 2019-08-14

心脏受累决定心脏淀粉样变性的预后和治疗选择。超声心动图是心力衰竭患者的一线检查,最常提示心脏淀粉样变性可疑,并可评估心脏淀粉样浸润可能性及严重程度。心脏磁共振(CMR)和骨闪烁显像正在改变诊断:CMR对轻链型和转甲状腺素蛋白型心肌淀粉样变性高度敏感和特异;骨闪烁显像联合血清游离轻链排除,正在成为区分转甲状腺素蛋白型与轻链型及其他心肌病的技术选择,使多数患者无需组织活检即可无创诊断转甲状腺素蛋白型淀粉样变性。

要点

  • 超声心动图是心力衰竭患者一线检查,最常提示心脏淀粉样变性可疑。
  • CMR增强后对轻链型和转甲状腺素蛋白型心肌淀粉样变性高度敏感和特异。
  • 骨闪烁显像联合血清游离轻链排除,正在成为区分转甲状腺素蛋白型与轻链型及其他心肌病的技术选择。

核心结论

  • 心脏受累驱动心脏淀粉样变性的预后和治疗选择。
  • CMR组织表征和骨闪烁显像正在改写疾病理解、分类和定义,并改变患者照护。

研究设计与样本

  • 本文为综述,检索范围与纳入文献原文未报告。

关键影像表现/征象

  • 超声心动图可评估心脏淀粉样浸润可能性与其他肥厚表型模拟者的鉴别,并评估心脏受累严重程度。
  • CMR结构功能评估联合组织表征可追踪从淀粉样浸润到淀粉样沉积相关心肌反应的不同疾病过程,并可视化和量化心肌水肿与心肌细胞反应。

诊断标准与关键数值

  • CMR增强后对轻链型淀粉样变性和转甲状腺素蛋白型淀粉样变性两种主要心室心肌淀粉样变性类型高度敏感和特异。
  • 骨闪烁显像联合血清游离轻链排除,可在多数患者中无需组织活检即无创诊断转甲状腺素蛋白型淀粉样变性。

临床应用与阅片要点

  • 心力衰竭患者首选超声心动图,并常由其提出心脏淀粉样变性可疑。
  • CMR增强联合组织表征用于鉴别轻链型与转甲状腺素蛋白型心肌淀粉样变性并评估受累。
  • 骨闪烁显像联合血清游离轻链排除用于区分转甲状腺素蛋白型与轻链型心脏淀粉样变性及其他心肌病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Cardiac involvement drives prognosis and treatment choices in cardiac amyloidosis. Echocardiography is the first-line examination for patients presenting with heart failure, and it is the imaging modality that most often raises the suspicion of cardiac amyloidosis. Echocardiography can provide an assessment of the likelihood of cardiac amyloid infiltration versus other hypertrophic phenocopies and can assess the severity of cardiac involvement. Visualizing myocardial amyloid infiltration is challenging and, until recently, was restricted to the domain of the pathologist. Two tests are transforming this: cardiac magnetic resonance (CMR) imaging and bone scintigraphy. After the administration of contrast, CMR is highly sensitive and specific for the 2 main types of ventricular myocardial amyloidosis, light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). CMR structural and functional assessment combined with tissue characterization can redefine cardiac involvement by tracking different disease processes, ranging from amyloid infiltration, to the myocardial response associated with amyloid deposition, through the visualization and quantification of myocardial edema and myocyte response. Bone scintigraphy (paired with exclusion of serum free light chains) is emerging as the technique of choice for distinguishing ATTR from light chain cardiac amyloidosis and other cardiomyopathies; it has transformed the diagnostic pathway for ATTR, allowing noninvasive diagnosis of ATTR without the need for a tissue biopsy in the majority of patients. CMR with tissue characterization and bone scintigraphy are rewriting disease understanding, classification, and definition, and leading to a change in patient care.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Fontana M, Ćorović A, Scully P, et al. Myocardial Amyloidosis: The Exemplar Interstitial Disease. JACC Cardiovasc Imaging. 2019. PMID: 31422120. doi:10.1016/j.jcmg.2019.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。